These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 36362428)

  • 21. Development of demyelinating lesions in progressive multifocal leukoencephalopathy (PML): Comparison of magnetic resonance images and neuropathology of post-mortem brain.
    Ono D; Shishido-Hara Y; Mizutani S; Mori Y; Ichinose K; Watanabe M; Tanizawa T; Yokota T; Uchihara T; Fujigasaki H
    Neuropathology; 2019 Aug; 39(4):294-306. PubMed ID: 31155757
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS.
    Gheuens S; Smith DR; Wang X; Alsop DC; Lenkinski RE; Koralnik IJ
    Neurology; 2012 May; 78(18):1390-3. PubMed ID: 22517104
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy.
    Dong-Si T; Gheuens S; Gangadharan A; Wenten M; Philip J; McIninch J; Datta S; Richert N; Bozic C; Bloomgren G; Richman S; Weber T; Clifford DB
    J Neurovirol; 2015 Dec; 21(6):637-44. PubMed ID: 25771865
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of natalizumab-associated PML with filgrastim.
    Stefoski D; Balabanov R; Waheed R; Ko M; Koralnik IJ; Sierra Morales F
    Ann Clin Transl Neurol; 2019 May; 6(5):923-931. PubMed ID: 31139690
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Probable progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome with immunosuppressant dose reduction following lung transplantation: a case report and literature review.
    Ishii K; Yamamoto F; Homma S; Okada Y; Nakamichi K; Saijo M; Tamaoka A
    BMC Neurol; 2019 Oct; 19(1):263. PubMed ID: 31672142
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Natalizumab-associated progressive multifocal leukoencephalopathy in a patient with multiple sclerosis: a postmortem study.
    Wüthrich C; Popescu BF; Gheuens S; Marvi M; Ziman R; Denq SP; Tham M; Norton E; Parisi JE; Dang X; Lucchinetti CF; Koralnik IJ
    J Neuropathol Exp Neurol; 2013 Nov; 72(11):1043-51. PubMed ID: 24128680
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Punctate pattern: A promising imaging marker for the diagnosis of natalizumab-associated PML.
    Hodel J; Darchis C; Outteryck O; Verclytte S; Deramecourt V; Lacour A; Zins M; Pruvo JP; Vermersch P; Leclerc X
    Neurology; 2016 Apr; 86(16):1516-23. PubMed ID: 27009257
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metabolic profiles by 1H-magnetic resonance spectroscopy in natalizumab-associated post-PML lesions of multiple sclerosis patients who survived progressive multifocal leukoencephalopathy (PML).
    Schneider R; Bellenberg B; Hoepner R; Kolb EM; Ellrichmann G; Haghikia A; Gold R; Lukas C
    PLoS One; 2017; 12(4):e0176415. PubMed ID: 28445498
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Natalizumab-associated cerebellar PML: a case report on how to slow down IRIS.
    Lauda F; Fangerau T; Javaheripour-Otto K; Pinkhardt E; Kassubek J; Tumani H
    J Neurol; 2015; 262(4):1055-7. PubMed ID: 25663412
    [No Abstract]   [Full Text] [Related]  

  • 30. Review of progressive multifocal leukoencephalopathy and natalizumab.
    Aksamit AJ
    Neurologist; 2006 Nov; 12(6):293-8. PubMed ID: 17122725
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The utility of FDG-PET imaging in distinguishing PML-IRIS from PML in a patient treated with natalizumab.
    Baheerathan A; McNamara C; Kalam S; Rane N; Barwick TD; Grote H; Nicholas R
    Neurology; 2018 Sep; 91(12):572-573. PubMed ID: 30224501
    [No Abstract]   [Full Text] [Related]  

  • 32. Presentation and Outcome in S1P-RM and Natalizumab-Associated Progressive Multifocal Leukoencephalopathy: A Multicenter Cohort Study.
    Blant JC; De Rossi NN; Gold R; Maurousset A; Kraemer M; Romero-Pinel L; Misu T; Ouallet JC; Pallix Guyot M; Gerevini S; Bakirtzis C; Piñar Morales R; Vlad B; Karypidis P; Moisset X; Derfuss TJ; Jelcic I; Martin-Blondel G; Ayzenberg I; McGraw C; Laplaud DA; Du Pasquier RA; Bernard-Valnet R;
    Neurol Neuroimmunol Neuroinflamm; 2024 Sep; 11(5):e200281. PubMed ID: 38991170
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Progressive multifocal leukoencephalopathy - immune reconstitution inflammatory syndrome (PML-IRIS) in liver transplant recipient.
    Avsenik J; Horvat Ledinek A; Šurlan Popovič K
    Mult Scler Relat Disord; 2017 Oct; 17():135-137. PubMed ID: 29055444
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TSPO PET imaging of natalizumab-associated progressive multifocal leukoencephalopathy.
    Mahler C; Schumacher AM; Unterrainer M; Kaiser L; Höllbacher T; Lindner S; Havla J; Ertl-Wagner B; Patzig M; Seelos K; Neitzel J; Mäurer M; Krumbholz M; Metz I; Brück W; Stadelmann C; Merkler D; Gass A; Milenkovic V; Bartenstein P; Albert NL; Kümpfel T; Kerschensteiner M
    Brain; 2021 Oct; 144(9):2683-2695. PubMed ID: 33757118
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients.
    Dahlhaus S; Hoepner R; Chan A; Kleiter I; Adams O; Lukas C; Hellwig K; Gold R
    J Neurol Neurosurg Psychiatry; 2013 Oct; 84(10):1068-74. PubMed ID: 23606731
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Radiological abnormalities in progressive multifocal leukoencephalopathy: Identifying typical and atypical imaging patterns for early diagnosis and differential considerations.
    Soni N; Ora M; Mangla R; Singh R; Ellika S; Agarwal A; Meyers SP; Bathla G
    Mult Scler Relat Disord; 2023 Sep; 77():104830. PubMed ID: 37418930
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome with intravenous immunoglobulin in a patient with multiple sclerosis treated with fingolimod after discontinuation of natalizumab.
    Calic Z; Cappelen-Smith C; Hodgkinson SJ; McDougall A; Cuganesan R; Brew BJ
    J Clin Neurosci; 2015 Mar; 22(3):598-600. PubMed ID: 25523125
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Presumptive progressive multifocal leukoencephalopathy in multiple sclerosis after natalizumab therapy.
    Eisele P; Szabo K; Hornberger E; Griebe M; Hennerici MG; Kieseier BC; Gass A
    J Neuroimaging; 2014; 24(4):425-8. PubMed ID: 23323645
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunological and clinical consequences of treating a patient with natalizumab.
    Schwab N; Höhn KG; Schneider-Hohendorf T; Metz I; Stenner MP; Jilek S; Du Pasquier RA; Gold R; Meuth SG; Ransohoff RM; Brück W; Wiendl H
    Mult Scler; 2012 Mar; 18(3):335-44. PubMed ID: 21908480
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Surgical management of malignant cerebral edema secondary to immune reconstitution inflammatory syndrome from natalizumab-associated progressive multifocal encephalopathy.
    Tan LA; Lopes DK
    J Clin Neurosci; 2015 Oct; 22(10):1669-71. PubMed ID: 26115897
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.